Domov › Steatotična bolezen jeter › Arizona › Tucson

Klinične študije za Steatotična bolezen jeter v Tucson, AZ

10 študij za Steatotična bolezen jeter išče udeležence na lokacijah v Tucson in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Vključevanje udeležencevFaza 3

89bio Clinical Study Site, Tucson
89bio Clinical Study Site, Tucson
89bio Clinical Study Site, Tucson

Starost 18–75 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06419374

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Vključevanje udeležencevFaza 3

89bio Clinical Study Site, Tucson
89bio Clinical Study Site, Tucson

Starost 18–80 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06318169

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Vključevanje udeležencevFaza 2

Arizona Liver Health - Tucson, Tucson

Starost 18–75 · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07527910

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Vključevanje udeležencevFaza 2

Adobe Clinical Research, Tucson
Arizona Liver Health - Tucson, Tucson
Del Sol Research Management, LLC, Tucson

Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05519475

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Vključevanje udeležencevFaza 3

The Institute for Liver Health II dba Arizona Clinical Trials - Tucson, Tucson
Del Sol Research Management, LLC, Tucson

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07165028

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Vključevanje udeležencevFaza 3

Akero Clinical Study Site, Tucson
Akero Clinical Study Site, Tucson
Akero Clinical Study Site, Tucson
in še 1

Starost 18–80 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06528314

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Vključevanje udeležencevFaza 2

Adobe Clinical Research, LLC, Tucson
Arizona Liver Health - Tucson, Tucson

Starost 18–75 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07288138

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

Vključevanje udeležencevFaza 2

GSK Investigational Site, Tucson
GSK Investigational Site, Tucson

Starost 18–70 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06613698

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Vključevanje udeležencevFaza 3

GSK Investigational Site, Tucson

Starost 18–75 · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT07221227

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Vključevanje udeležencevFaza 2

GSK Investigational Site, Tucson

Starost 18–75 · Vsi spoli · Posodobljeno 8. jul. 2026 · NCT06920043

Študije za Steatotična bolezen jeter v drugih mestih

Druge študije v Tucson

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.